“
“Supratentorial hemangioblastoma is a rare form of hemangioblastoma; little information is available regarding prognosis, treatment, and clinical characteristics, signaling pathway because the available literature is primarily composed of case reports and small case series. Therefore, we performed

a systematic review of the literature to analyze clinical characteristics, disease progression, and surgical outcomes with respect to survival for supratentorial hemangioblastomas. The rate of progression-free survival (PFS) was determined using Kaplan-Meier analysis. Differences in categorical factors, including location of tumor and diagnosis of von Hippel-Lindau (VHL) disease, were analyzed using the Pearson (2) test. A total of 106 articles met the Bromosporine solubility dmso search criteria, which combined for a total of 132 patients. Of the patients with supratentorial tumors, 60 had VHL disease, and 31 (84) of 37 patients with tumors in the sellar/suprasellar region had associated VHL ((2), P .001). Five-year PFS for gross-total resection and subtotal resection were 100 and 53, respectively (Log rank, P .01). On the basis of our analysis of the literature on published cases of supratentorial hemangioblastoma,

gross-total resection appears to be superior to other treatment modalities in extending PFS. Von HippelLindau disease is positively correlated with supratentorial hemangioblastoma when compared with non-supratentorial CNS hemangioblastomas,

particularly when present in the sellar/suprasellar Daporinad region.”
“Intravenous cyclophosphamide (IVCY) has been used to treat severe lupus nephritis (LN) for many years. Because of the wide variety of manifestations of the condition and the long-term nature of the disease, outcomes vary widely.\n\nTo evaluate and compare the immediate and long-term results of IVCY in pediatric onset severe LN and between patients with normal and abnormal initial renal function.\n\nPatients aged < 18 years who attended the Department of Pediatrics, Prince of Songkla University, diagnosed with severe LN, and who were given a 36-month IVCY course, were included. Comparison of overall survival between the two groups was assessed using Kaplan-Meier survival curves.\n\n108 patients with a mean age of 12.6 +/- A 2.7 years were studied, with a mean follow-up time of 5.7 +/- A 4.3 years. 48 patients completed the IVCY course. 36 patients had abnormal renal function and 72 patients had normal renal function at the start of therapy. Both groups responded well initially to treatment; proteinuria reduced to normal levels after 1 and 2 treatments in the normal and abnormal groups, respectively, while creatinine clearance returned to normal levels after 8 treatments in the abnormal group.